Biomarin Pharmaceutical (WBO:BMRN) Land And Improvements : €0 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical Land And Improvements?

Biomarin Pharmaceutical's land and improvements for the quarter that ended in Mar. 2024 was €0 Mil.

Biomarin Pharmaceutical's quarterly land and improvements increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€108 Mil) but then declined from Dec. 2023 (€108 Mil) to Mar. 2024 (€0 Mil).

Biomarin Pharmaceutical's annual land and improvements increased from Dec. 2021 (€89 Mil) to Dec. 2022 (€111 Mil) but then declined from Dec. 2022 (€111 Mil) to Dec. 2023 (€108 Mil).

Biomarin Pharmaceutical Land And Improvements Historical Data

The historical data trend for Biomarin Pharmaceutical's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Land And Improvements Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

87.99

80.42

88.99

110.68

107.80

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Land And Improvements	Get a 7-Day Free Trial															-	-	-	107.80	-

Biomarin Pharmaceutical Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Biomarin Pharmaceutical (WBO:BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.